Join
Live feed
·
PRReleasevia Quantisnow
Orchard Therapeutics plc logo

Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-of-concept Study of OTL-201 in MPS-IIIA

ByQuantisnow·Wall Street's wire, on your screen.
ORTX· Orchard Therapeutics plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ORTX (Orchard Therapeutics plc) and more on Quantisnow.